Accelerating the Biomanufacturing Revolution

The report argues that the biomanufacturing revolution, driven by synthetic biology and falling costs in DNA sequencing, offers a $4 trillion annual opportunity to replace petrochemical inputs and address global crises. It emphasizes the need for strategic partnerships between platform companies and product manufacturers to bridge the gap between biological design and commercial product success. The document specifically highlights the importance of 'pre-competitive bioprocess demonstration facilities' to overcome bottlenecks in downstream processing. Additionally, it calls for a workforce transformation to create 'cyan-collar' jobs—skilled manufacturing roles at the intersection of green technology and traditional industry—drawing parallels to the growth of the ICT sector.

• The global bioeconomy is estimated to reach an annual value of $4 trillion over the next decade, with the potential for biomanufacturing to provide up to 60% of the physical inputs to the global economy.
• Biomanufacturing can address critical environmental and security challenges, including the bioremediation of wastewater, the biosequestration of greenhouse gases, and the rapid production of pharmaceuticals during pandemics to enhance biosecurity.
• A significant gap exists between upstream biological production (fermentation) and downstream processing (purification and isolation), creating a need for pre-competitive bioprocess demonstration facilities to reduce the financial risk for startups.
• Strategic partnerships between synthetic biology pioneers and established brands can accelerate the adoption of sustainable materials, such as the collaboration between Genomatica and Lululemon to produce bio-nylon, which aims to eliminate 60 million tonnes of nitrous oxide emissions.
• The biomanufacturing revolution is creating a new category of 'cyan-collar' jobs, which blend sustainable green technologies with traditional blue-collar manufacturing and are particularly relevant for rural areas where agricultural feedstocks are located.
• Singapore serves as a model for biopharma development, having increased its pharma sector manufacturing output more than 3X since 2000, producing over $16 billion in products and attracting 8 of the top 10 global pharmaceutical companies.

APA

World Economic Forum (2022). Accelerating the Biomanufacturing Revolution. https://www3.weforum.org/docs/WEF_Accelerating_the_Biomanufacturing_Revolution_2022.pdf

Chicago

World Economic Forum. Accelerating the Biomanufacturing Revolution. 2022. https://www3.weforum.org/docs/WEF_Accelerating_the_Biomanufacturing_Revolution_2022.pdf.

Wikipedia

{{cite report |author=World Economic Forum |title=Accelerating the Biomanufacturing Revolution |date=February 2022 |url=https://www3.weforum.org/docs/WEF_Accelerating_the_Biomanufacturing_Revolution_2022.pdf |access-date=23 October 2026 |via=Climate Insights Directory}}

BibTeX

@techreport{worldeconomicforum2022accelerating, author = {{World Economic Forum}}, title = {{Accelerating the Biomanufacturing Revolution}}, institution = {World Economic Forum}, year = {2022}, month = feb, url = {https://www3.weforum.org/docs/WEF_Accelerating_the_Biomanufacturing_Revolution_2022.pdf}, urldate = {2026-10-23}, note = {Indexed by Climate Insights Directory} }